The Zhitong Finance App learned that on Wednesday, Zaiding Pharmaceutical (ZLAB.US) rose more than 8% to $27.44. According to the news, on August 31, Zaiding Pharmaceutical registered a global phase III clinical trial of ZL-1310+ PD-L1 antibody first-line treatment for ES-SCLC on the ClinicalTrials.gov website. The global phase III clinical trial is intended to enroll 530 first-line ES-SCLC patients and is expected to be initially completed in June 2030.

Zhitongcaijing · 3d ago
The Zhitong Finance App learned that on Wednesday, Zaiding Pharmaceutical (ZLAB.US) rose more than 8% to $27.44. According to the news, on August 31, Zaiding Pharmaceutical registered a global phase III clinical trial of ZL-1310+ PD-L1 antibody first-line treatment for ES-SCLC on the ClinicalTrials.gov website. The global phase III clinical trial is intended to enroll 530 first-line ES-SCLC patients and is expected to be initially completed in June 2030.